#### 4<sup>th</sup> year of the Prague Summer School ADVANCES IN DRUG DISCOVERY

DRUG discovery and DEVELOPMENT from basic research through preclinical to clinical phases



Prague, Czech Republic September 4<sup>th</sup> – 8<sup>th</sup>, 2017

# PROGRAMME

The course is organized by the University of Chemistry and Technology Prague and Institute of Organic Chemistry and Biochemistry of the CAS



UNIVERSITY OF CHEMISTRY AND TECHNOLOGY PRAGUE



#### MEETING VENUE University of Chemistry and Technology Prague BUILDING A, ROOM AI (Technická 5, Prague 6)

	MONDAY, SEPTEMBER 4 <sup>th</sup>	
11:00	Registration at University of Chemistry and Technology Prague (UCT)	
14:00	Welcome from the IOCB director & UCT rector Zdeněk Hostomský (Director IOCB) Karel Melzoch (UCT rector) Opening Talks	
14:20	Helena Mertlíková (IOCB) Overview of the Process	
15.00	Coffee break	
15:20	Dorte X. Gram (CEO) If I'm right, This could be a really Big Thing! – Daring to Challenge Status-quo in Diabetes Treatment	
16:00	Jiří Paleček (FGU) Pain, Research and Challenging Path for New Treatments	
18:00	Welcome Party at Masaryk Dormitory (address: Thákurova 1, Prague 6)	
TUESDAY, SEPTEMBER 5th		
9:00	James Engel (University of Michigan) Developing Therapeutics for the Worlds Most Common Inherited Genetic Disease	
9:45	Petr Váchal (MSD) Medicinal Chemistry Enabled by Novel, Transformational Capabilities	
10:30	Coffee break	
10:45	Stanislav Rádl (Zentiva) Deuterated Drugs – A Hot Topic of Current Medicinal Chemistry	
11:30	Stephane Daffis (Gilead) Drug Discovery and Development Strategies for HBV Cure	
12:15	Lunch at Masaryk Dormitory	

14:00	Thomas Ullrich (Novartis) Local Drug Delivery to Joints and Tendon
14:45	Evžen Bouřa (IOCB) Rational structure-based drug design – practical experiences
15:30	IOCB Tour (meeting point registration desk)

#### WEDNESDAY, SEPTEMBER 6<sup>th</sup>

9:00	Ivana Šurová (MediTox s.r.o.) Preclinical Toxicology – an Important Part of Drug Development
9:45	Ivana Šurová (MediTox s.r.o.) Preclinical Toxicology and its Relevance to Clinical Trials
10:30	Coffee break
10:45	Vít Perlík (Independent consultant) Clinical Trials in Drug Development
11:30	Piotr Golkiewicz (Elsevier) Quick access to collated data on bioactivity of chemical compounds with help of Reaxys Medicinal Chemistry
12:15	Lunch at Masaryk Dormitory
14:30	Prague City Tour and dinner (restaurant Staré časy – address Rytířská 4, Prague 1)

#### THURSDAY, SEPTEMBER 7<sup>th</sup>

9:00	Sergey Zozulya (ENAMINE) Discovering Drugs with a CRO
9:45	Ernst Plefka (Biocrates) Pharmacometabolomics in Drug Development and Precision Medicine
10:30	Coffee break
10:45	Stephan Bachmann (Roche) Catalysis as Key Technology in the Synthesis & Scale-up of APIs and Their Intermediates
11:30	Dan Svozil (UCT Prague) Introduction to Chemoinformatics and Computational Drug Design
12:15	Lunch at Masaryk Dormitory
13:30	Marián Hajdůch (IMTM) Personalized Medicine in Oncology
14:15	Tomáš Etrych (IMC) Nanosized Polymer-based Medicines for Targeted Therapy
15:00	UCT Tour and Visit of the University Brewery (meeting point registration desk)

	FRIDAY, SEPTEMBER 8th
9:00	Igor Linhart (UCT Prague) Clandestine Drug Design: From Mere Copying to New Psychoactive Substances
9:45	Pavlína Řezáčová (UMG) X-ray Crystalography in Drug Design
10:30	Coffee break
10:45	David M.Andrews (Astra Zeneca) The discovery of AZD4547
11:30	Eva Kudová (IOCB) Architecture in the Syntesis of Steroidal Inhibitors of NMDA Receptors: Do Built New or Rebuilt Old?
12:15	Václav Veverka (IOCB) NMR and Drug Development
13:00	CLOSING, BEST POSTER AWARD WINNER
13.30	Lunch at Masaryk Dormitory



UCT Prague, room Al

### **LIST OF POSTERS**

	Last Name	First Name	Name of Absract
P1	Andranovits	Stanislav	Key role of segment IS4 in Cav1.2 inactivation: link between activation and inactivation
P2	Andrs	Martin	The development of novel compounds with radio- and chemosensitizing properties based on the phosphatidylinositol 3-kinase inhibitor LY294002
P3	Bekić	Sofija	Evaluation of the steroid receptor binding affinity of some selected steroid derivatives by fluores- cent cellular biosensor
P4	Bor	Gizem	ТВА
P5	Górecki	Lukáš	Mono-quaternary reactivators, new lead structures for organophosphorus intoxication.
P6	Chechina	Nataliia	Arylglyoxals as convenient precursors for the syn- thesis of heterocyclic compounds
P7	lbba	Roberta	Design and synthesis of new planar heteroaro- matic derivatives with antiviral activity
P8	Janočková	Jana	Inhibition of Aβ1-42 self-aggregation process
Р9	Janovská	Pavlína	Casein kinase 1 δ/ε is a therapeutic target in chronic lymphocytic leukemia (CLL)
P10	Kobrlová	Tereza	In vitro PAMPA and MDCK models for the predic- tion of blood brain barrier penetration
P11	Kodedová	Marie	The mechanism of action of halictines is depen- dent on the lipid composition of Candida cells
P12	Korábečný	Jan	Design, synthesis and in vitro evaluation of novel 7-methoxytacrine-adamantylamine hybrids: Novel cholinesterase inhibitors with potential implication for Alzheimer's disease treatment

P13	Kučera	Tomáš	Anti-Alzheimer or antimalarial drugs? Usage of the cross-docking in drug design
P14	Levin	Maxim	Engineering novel protein agents to study and manipulate the extracellular matrix
P15	Marchetti	Giuseppe	In vitro and computational studies of Syk inhibi- tors as new antimalarial drugs
P16	Marinovič	Maja	Use of crystallographic data, molecular dynamics and A Fluorescent cell assay to identify ligands with selectivity for estrogen or androgen recep- tor isoforms
P17	Mezeiová	Eva	Development of novel huprine derivative for Alzheimer's disease therapy
P18	Mohl	Gregory	In silico design and structure-activity relationship of novel influenza inhibitors
P19	Morozová	Alisa	Domino reactions of 3(5)-aminoisoxazoles and pyruvic acid's derivatives
P20	Němec	Václav	Discovery of new protein kinase inhibitors with the furo [3,2-b]pyridine core
P21	Pavlovská	Tetyana	Spiropyrrolidineoxindoles as potential drug candidates in target-oriented synthesis
P22	Plavša	Jovana	Identification of potential inhibitors of AKR1C3 and preparation for structural analyses.
P23	Repich	Hlib	Pi-coordination compounds of Pd(II) and Pt(II) as potential substitutes of cisplatin and its analogues
P24	Sanin	Eduard	Bright fluorescent squaraine rotaxanes for bio- medical applications
P25	Shraga	Amit	Novel covalent inhibitors of the MKK7 kinase
P26	Stadler	Marco	Pharmacological characterization of a GLIC-GABAA beta3 chimera

P27	Szánti-Pintér	Eszter	Claisen-Schmidt condensation of 17-ketosteroids in the presence of switchable polarity solvents
P28	Tomas	Jan	Importance of tablet disintegration for pharma- ceutical product performance: New approaches using texture analysis.
P29	Tubon Usca	Irvin Ricardo	Effects of ethanolic extracts of four ecuadorian plants on porcine aortic endothelial cells (pAECs) stability.
i i		1	
P30	Tulli	Ludovico	Dendrimers as polyfunctional scaffolds for mass cytometry applications
P30 P31	Tulli Vaca Altamirano	Ludovico Gabriela Liseth	1 2



**UOCHB** Building



DRUG discovery and DEVELOPMENT from basic research through preclinical to clinical phases



The Deep Phenotyping Company







ELSEVIER

## lach:ner

Project TE01020028 / Center for Development of Original Drugs is realized with financial support from the Technology Agency of the Czech Republic (TA ČR).

T A Č R

#### Organizing Secretariat: Congress Business Travel

Lidická 43/66 150 00 Prague 5 – Anděl Czech Republic Phone: +420 224 942 575, +420 224 942 579 Fax: +420 224 942 550 E-mail: praguesummerschool@cbttravel.cz



#### www.praguesummerschool.cz